Clinical trials targeting the Wnt-β-catenin and PI3K/mTOR pathways and oncogenic p53 mutants (https://clinicaltrials.gov/ct2/show/NCT03149679, accessed on 9 June 2021) in CRC are ongoing [340,341]. This evidence concerns the gene TP53 and colorectal carcinoma.